Medigene (ETR:MDG1) Shares Down 4.4%

Medigene AG (ETR:MDG1) dropped 4.4% during trading on Wednesday . The company traded as low as €1.20 ($1.29) and last traded at €1.20 ($1.29). Approximately 34,326 shares were traded during trading, a decline of 89% from the average daily volume of 306,207 shares. The stock had previously closed at €1.26 ($1.35).

Medigene Stock Performance

The company has a current ratio of 2.53, a quick ratio of 5.85 and a debt-to-equity ratio of 14.00. The firm’s fifty day moving average price is €1.48 and its 200 day moving average price is €1.56. The firm has a market capitalization of $35.38 million, a PE ratio of -1.90, a PEG ratio of 7.12 and a beta of 0.91.

Medigene Company Profile

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.